Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
αPD1-MSLN-CAR T cells in advanced solid tumors
NCT04489862Phase 1Unknown
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZD1901 in solid tumor, non-small cell lung cancer (NSCLC) and mesothelioma. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
BZD1901
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NCT04489862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489862.